Scott Gottlieb Quotes


Americans broadly consent to funding clinical research because they believe in the promise of medical research. But people support scientific work only if they trust that it serves societal interests, respects patient dignity and operates with guardrails.


Citations

Gottlieb, Scott. "The Guardrails on Medical Research." The Wall Street Journal, 2019.

Related Quotes

She led a study in the late 1950s where they collected 300,000 St Louis resident’s baby teeth with the ages of the time of collection and the data of birth. She and her colleagues were able to show that after each of the post WWII Nuclear Tests, the level of Strontium 90 increased in the teeth of the children. The results were published in the prestigious scientific journal Science in 1961. The study was presented to Congress by her husband—also a physician and it was also considered by President John F. Kennedy. It was also shared with the Russians and shortly thereafter the first of the Test Ban treaties was signed. At the time politicians had more respect for science than became the norm in the beginning of the 21st century but she retained her faith in the political process integrating and being informed by science. See {640558}.


Scott Gottlieb
Scott Gottlieb
  • Born: June 11, 1972
  • Nationality: American
  • Profession: Public Servant

Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, a member of the board of directors of Illumina, Inc., and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner, he was a clinical assistant professor at New York University School of Medicine, the FDA deputy commissioner for medical and scientific affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare and Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.